jeudi 20 août 2015
mercredi 19 août 2015
Without ABI and post exercise ABI duplex of the lower limbs is waste of money
http://www.medpagetoday.com/Cardiology/Prevention/53103?xid=nl_mpt_DHE_2015-08-18&eun=g432148d0r
http://www.sciencedirect.com/science/article/pii/S1936879815008419
http://www.sciencedirect.com/science/article/pii/S1936879815008407
http://www.sciencedirect.com/science/article/pii/S1936879815008419
http://www.sciencedirect.com/science/article/pii/S1936879815008407
 |
Figure 1.
Unadjusted Kaplan-Meier Curves in All 4 ABI Groups for Lower Extremity Revascularization
The log-rank test revealed a statistically significant difference between the lower extremity revascularization rates across all 4 groups over time (p < 0.001). ABI = ankle-brachial index; AE = abnormal ankle-brachial index post exercise; AR = abnormal ankle-brachial index at resting; NE = normal ankle-brachial index post exercise; NR = normal ankle-brachial index at resting.
|
 |
| Figure 3.
Unadjusted Kaplan-Meier Curves in All 4 ABI Groups for All-Cause Mortality
The log-rank test revealed statistically significant different all-cause mortality rates across all 4 ABI groups over time (p < 0.001). Abbreviations as in Figure 1.
|
Boire ou jouir il va falloir choisir: Flibanserin une incroyable discrimination de Big Pharma...
The counterpart of Sildenafil is approved! Its name in the media is Female Viagra. The drug is intended to increase libido in premenopausal women. What is the diagnosis? Sexual dysfunction and symptoms of unsatisfied intercourses.
Sexual dysfunction as an independent disease? As for men a major question is: will the drug be used for improvement of satisfaction above normal? In other words is Flibanserin a drug for performance a dope? For sure it will. But be careful without alcohol.
""Because of a potentially serious interaction with alcohol, treatment with Addyi will only be available through certified health care professionals and certified pharmacies," Woodock added. The FDA ordered a Risk Evaluation and Mitigation Strategies (REMS) program that mandates special training for prescribers.
The label will include a boxed warning to underscore the risks of severe hypotension and syncope among patients who drink alcohol while taking the drug and for women who use "moderate or strong CYP3A4 inhibitors" and those with liver impairments. Addyi is contraindicated for all such patients."
"All three trials conducted by the sponsor showed "statistically significant improvement" in the number of satisfying sexual events (SSE) and a reduction of sex-related distress in participants taking flibanserin compared with control participants, according to FDA reviewers. The sponsor drug also showed a median placebo-corrected increase of approximately 0.5-1.0 SSEs per month, from the median baseline of two to three events per month."